Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue

[SINGAPORE] Drug development typically takes six to 10 years just to identify a viable molecule, but Singapore biotech firm Nanyang Biologics reckons it can do the job in six minutes.

Originally founded as a biopharma startup to develop cancer and cardiovascular therapies, the company simultaneously spent six years building an artificial intelligence (AI) platform to accelerate its own drug discovery work.

Now it has commercialised that technology as NYB.AI, positioning it as a tool for pharmaceutical and health supplement manufacturers looking to slash costs and timelines.